Oncology Hospital-to-Home (H2H) Drug Administration Market Size, Share & Trends Analysis Distribution By Therapy Type( Immunotherapy, Targeted Therapies, Maintenance Chemotherapy, Hormonal Therapy, Supportive Oncology Care, Palliative Oncology Infusions), By Service Type (Home Infusion Nursing, Home Chemotherapy Administration, Home-Based SC Oncology Injection Services, Pharmacy Compounding & Dispensing, Care Coordination & Scheduling), By Delivery Volume Capacity, By End Users and By Segments Forecasts, 2025-2034

Report Id: 3343 Pages: 170 Last Updated: 10 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentations of Oncology Hospital-to-Home (H2H) Drug Administration Market :

Oncology Hospital-to-Home (H2H) Drug Administration Market by Therapy Type

  • Immunotherapy 
  • Targeted Therapies
    • ADC supportive regimens
    •  SC biologics used in home setting
  • Maintenance Chemotherapy
  • Hormonal Therapy
  • Supportive Oncology Care
    • G-CSF (Neulasta Onpro, etc.)
    •  Anti-nausea infusion therapy
    • IV hydration & pain management
  • Palliative Oncology Infusions 

Oncology Hospital-to-Home (H2H) Drug Administration Market

Oncology Hospital-to-Home (H2H) Drug Administration Market by Service Type:

  • Home Infusion Nursing
  • Home Chemotherapy Administration
  • Home-Based SC Oncology Injection Services
  • Pharmacy Compounding & Dispensing
  • Care Coordination & Scheduling
  • Remote Vitals Monitoring / Tele-oncology
  • Patient Education & Toxicity Management
  • Drug Delivery Logistics & Cold Chain

Oncology Hospital-to-Home (H2H) Drug Administration Market by Provider Type

  • Home Infusion Companies
  • Specialty Oncology Pharmacies
  • Integrated Health System Programs
  • Nurse Workforce Management Companies

Oncology Hospital-to-Home (H2H) Drug Administration Market by Case Model

  • Hospital-Led Home Oncology Programs
  • Payer-Led Value-Based Home Cancer Care
  • Integrated Oncology-at-Home Care Teams
  • Remote Oncology + Nurse Visit Hybrid Model

Oncology Hospital-to-Home (H2H) Drug Administration Market by Reimbursement Model

  • Private Insurance Reimbursement
  • Medicare/Medicaid (US)
  • Capitated Contracts with Hospitals
  • Out-of-Pocket & Direct Pay (Emerging Markets)

Oncology Hospital-to-Home (H2H) Drug Administration Market by Patient Setting

  • Acute Oncology at Home
  • Maintenance Therapy at Home
  • Chronic Oncology Care at Home
  • End-stage / Palliative Home Oncology

Oncology Hospital-to-Home (H2H) Drug Administration Market By Region-

  • North America-
    • The US
    • Canada
  • Europe-
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific-
    • China
    • Japan
    • India
    • South Korea
    • South East Asia
    • Rest of Asia Pacific
  • Latin America-
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Middle East & Africa-
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Oncology Hospital-to-Home (H2H) Drug Administration Market Snapshot

Chapter 4. Oncology Hospital-to-Home (H2H) Drug Administration Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends 
4.5. Investment and Funding Analysis 
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034 
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Oncology Hospital-to-Home (H2H) Drug Administration Market Industry Trends 
4.10. Global Oncology Hospital-to-Home (H2H) Drug Administration Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034

Chapter 5. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 1: By Therapy Type Estimates & Trend Analysis
5.1. Market Share by Therapy Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:

5.2.1. Immunotherapy 
5.2.2. Targeted Therapies

5.2.2.1. ADC supportive regimens
5.2.2.2. SC biologics used in home setting

5.2.3. Maintenance Chemotherapy
5.2.4. Hormonal Therapy
5.2.5. Supportive Oncology Care

5.2.5.1. G-CSF (Neulasta Onpro, etc.)
5.2.5.2. Anti-nausea infusion therapy
5.2.5.3. IV hydration & pain management

5.2.6. Palliative Oncology Infusions 

Chapter 6. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 2: By Service Type, Estimates & Trend Analysis
6.1. Market Share by Service Type, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Service Type:

6.2.1. Home Infusion Nursing
6.2.2. Home Chemotherapy Administration
6.2.3. Home-Based SC Oncology Injection Services
6.2.4. Pharmacy Compounding & Dispensing
6.2.5. Care Coordination & Scheduling
6.2.6. Remote Vitals Monitoring / Tele-oncology
6.2.7. Patient Education & Toxicity Management
6.2.8. Drug Delivery Logistics & Cold Chain 

Chapter 7. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 3: Provider Type, Estimates & Trend Analysis
7.1. Market Share by Provider Type, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Provider Type:

7.2.1. Home Infusion Companies
7.2.2. Specialty Oncology Pharmacies
7.2.3. Integrated Health System Programs
7.2.4. Nurse Workforce Management Companies 

Chapter 8. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 4: Case Model, Estimates & Trend Analysis
8.1. Market Share by Case Model, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Case Model:

8.2.1. Hospital-Led Home Oncology Programs
8.2.2. Payer-Led Value-Based Home Cancer Care
8.2.3. Integrated Oncology-at-Home Care Teams
8.2.4. Remote Oncology + Nurse Visit Hybrid Model 

Chapter 9. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 5: By Patient Setting, Estimates & Trend Analysis
9.1. Market Share by Patient Setting, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Patient Setting:

9.2.1. Acute Oncology at Home
9.2.2. Maintenance Therapy at Home
9.2.3. Chronic Oncology Care at Home
9.2.4. End-stage / Palliative Home Oncology 

Chapter 10. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 6: By Reimbursement Model, Estimates & Trend Analysis
10.1. Market Share by Reimbursement Model, 2024 & 2034
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Reimbursement Model:

10.2.1. Private Insurance Reimbursement
10.2.2. Medicare/Medicaid (US)
10.2.3. Capitated Contracts with Hospitals
10.2.4. Out-of-Pocket & Direct Pay (Emerging Markets) 

Chapter 11. Oncology Hospital-to-Home (H2H) Drug Administration Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. Global Oncology Hospital-to-Home (H2H) Drug Administration Market, Regional Snapshot 2024 & 2034
11.2. North America

11.2.1. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.2.1.1. US
11.2.1.2. Canada

11.2.2. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.2.3. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
11.2.4. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Provider Type, 2021-2034
11.2.5. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Case Model, 2021-2034
11.2.6. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Patient Setting, 2021-2034
11.2.7. North America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Reimbursement Model, 2021-2034

11.3. Europe

11.3.1. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain

11.3.1.6. Rest of Europe

11.3.2. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.3.3. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
11.3.4. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Provider Type, 2021-2034
11.3.5. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Case Model, 2021-2034
11.3.6. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Patient Setting, 2021-2034
11.3.7. Europe Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Reimbursement Model, 2021-2034

11.4. Asia Pacific

11.4.1. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.4.1.1. India 
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific

11.4.2. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.4.3. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
11.4.4. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Provider Type, 2021-2034
11.4.5. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Case Model, 2021-2034
11.4.6. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Patient Setting, 2021-2034
11.4.7. Asia Pacific Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Reimbursement Model, 2021-2034

11.5. Latin America

11.5.1. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America

11.5.2. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.5.3. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
11.5.4. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Provider Type, 2021-2034
11.5.5. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Case Model, 2021-2034
11.5.6. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Patient Setting, 2021-2034
11.5.7. Latin America Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Reimbursement Model, 2021-2034

11.6. Middle East & Africa

11.6.1. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.6.1.1. GCC Countries
11.6.1.2. South Africa
11.6.1.3. Rest of Middle East and Africa

11.6.2. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.6.3. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
11.6.4. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Provider Type, 2021-2034
11.6.5. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Case Model, 2021-2034
11.6.6. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Patient Setting, 2021-2034
11.6.7. Middle East & Africa Oncology Hospital-to-Home (H2H) Drug Administration Market Revenue (US$ Million) Estimates and Forecasts by Reimbursement Model, 2021-2034

Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
 

12.2.1. CareCentrix
12.2.2. Naven Health
12.2.3. Option Care Health
12.2.4. Onco360
12.2.5. Amerita
12.2.6. McKesson
12.2.7. Accredo
12.2.8. Amber Specialty Pharmacy
12.2.9. Sciensus
12.2.10. Lloyds Clinical (LloydsPharmacy Clinical Homecare)
12.2.11. CarepathRx
12.2.12. BioScrip (Option Care Health – legacy)
12.2.13. Others

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5625
Security Code field cannot be blank!

Frequently Asked Questions

Oncology Hospital-to-Home (H2H) Drug Administration Market is predicted to grow at a 14.6% CAGR during the forecast period for 2025-2034.

CareCentrix, Naven Health, Option Care Health, Onco360, Amerita, McKesson, Accredo, Amber Specialty Pharmacy, Sciensus, Lloyds Clinical (Lloyds Pharmacy Clinical Homecare), CarepathRx, BioScrip (Option Care Health – legacy), Others

Therapy Type, Service Type, Provider Type, Case Model, Patient Setting and Reimbursement Model are the key segments of the Oncology Hospital-to-Home (H2H) Drug Administration Market.

North America region is leading the Oncology Hospital-to-Home (H2H) Drug Administration Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying